Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review
Open Access
- 2 June 2020
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 12 (6) , e8415
Abstract
COVID-19 represents a global health crisis. Several studies are evaluating potential therapies including hydroxychloroquine (HCQ) which is given to patients based on limited observational evidence. However, it can cause serious adverse events. Moreover, recent studies showed no benefits due to HCQ. We present two COVID-19 patients treated with HCQ and had adverse events.Keywords
This publication has 4 references indexed in Scilit:
- RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infectionMedecine Et Maladies Infectieuses, 2020
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)JAMA, 2020
- Determinants of Prolonged QT Interval and Their Contribution to Sudden Death Risk in Coronary Artery DiseaseCirculation, 2009